TOP TEN perturbations for 1077_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1077_at
Selected probe(set): 206591_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1077_at (206591_at) across 6672 perturbations tested by GENEVESTIGATOR:

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):6.8087063
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

ALL study 3 (8d) / ALL study 3 (0d)

Relative Expression (log2-ratio):-6.0970554
Number of Samples:2 / 2
Experimental ALL study 3 (8d)
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken 8 days after remission-induction therapy (RIT).
Control ALL study 3 (0d)
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).

PMA study 3 (shRNA contr.) / mock treated / transduced Jurkat cell sample

Relative Expression (log2-ratio):-5.8200884
Number of Samples:2 / 2
Experimental PMA study 3 (shRNA contr.)
Jurkat cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated / transduced Jurkat cell sample
Jurkat cells were transduced with a control shRNA and then mock treated.

ALL study 2 (33d) / ALL study 2 (0d)

Relative Expression (log2-ratio):-5.3043194
Number of Samples:58 / 129
Experimental ALL study 2 (33d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 33 days after remission-induction therapy (RIT).
Control ALL study 2 (0d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).

PMA study 3 (shRNA cycT1) / cycT1 depletion study 1 (shRNA)

Relative Expression (log2-ratio):-5.1889114
Number of Samples:2 / 2
Experimental PMA study 3 (shRNA cycT1)
Jurkat cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control cycT1 depletion study 1 (shRNA)
Jurkat cells were transduced with shRNA against cyclin T1 and then mock treated.

ALL study 2 (15d) / ALL study 2 (0d)

Relative Expression (log2-ratio):-4.528946
Number of Samples:45 / 129
Experimental ALL study 2 (15d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 15 days after remission-induction therapy (RIT).
Control ALL study 2 (0d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):-4.228382
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):4.108773
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (E2A-PBX1) / precursor-B-ALL study 3 (TEL-AML1)

Relative Expression (log2-ratio):-4.043518
Number of Samples:6 / 15
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (TEL-AML1) / T-ALL study 3

Relative Expression (log2-ratio):4.042721
Number of Samples:15 / 29
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).